KVUE is the ticker symbol for Kenvue Inc., a publicly traded Consumer Staples sector company listed on NYSE. 13F Pro tracks KVUE with AI-powered analysis, a 32-signal quality score, SEC EDGAR financials, insider transactions, and institutional 13F holdings — all sourced directly from public SEC filings.

Is KVUE a good stock to buy?

13F Pro's AI ranking engine scores KVUE at 60.3/100, ranked #865 of 2,961 stocks based on 32 fundamental signals including profitability, growth, balance sheet strength, and free cash flow. The full AI verdict and bull/bear case for KVUE is available at https://13fpro.ai/company/KVUE. Not investment advice — review the underlying SEC filings before making any trade.

Where does 13F Pro source KVUE data?

All Kenvue Inc. fundamentals and ownership data come directly from SEC EDGAR. Kenvue Inc. files with the SEC under CIK 1944048. 13F Pro ingests XBRL financial facts from 10-K and 10-Q filings, Form 13F-HR institutional holdings, and Form 4 insider transactions, with no third-party rewrites or estimates.

Kenvue Inc.(KVUE)— Stock Profile, AI Score & Financials

Consumer Staples · NYSE · AI-powered stock analysis, 32-signal quality score, SEC EDGAR financials, and institutional holdings. Updated 2026-06-28.

Kenvue Inc. (KVUE) stock profile, AI quality score, and SEC EDGAR financial data, a Consumer Staples sector company. 13F Pro's AI-powered ranking engine scores KVUE at 60.3/100 on a 32-signal composite quality model, placing it at rank #865 of 2,961 stocks — the top half of the AI-ranked universe. KVUE scores in the top quartile across revenue scale (90.4). Areas of concern include revenue growth (23.8), which score below median versus the broader universe. Based on the latest XBRL financial filings (Q2 2026), Kenvue Inc. reports quarterly revenue of $4.0B, net income of $456.0M, an operating margin of 17.7%. Top institutional holders of KVUE by reported 13-F value include FMR, BlackRock, VANGUARD CAPITAL MANAGEMENT, based on the most recent SEC filings. KVUE trades on the NYSE exchange and files with the SEC under CIK 1944048. 13F Pro's AI research platform runs 10 specialized AI analysts — value, growth, momentum, macro, and activist specialists — that debate KVUE daily and publish AI-generated analysis with cited SEC sources. The platform aggregates historical XBRL financial facts, 10-Q and 10-K filings, insider Form 4 transactions, and institutional 13-F holdings for Kenvue Inc. directly from SEC EDGAR.

AI Quality Score

60.3/100

AI Rank

#865

Revenue

$4.0B

Net Income

$456.0M

Free Cash Flow

$624.0M

Operating Margin

17.7%

KVUE key financials by period

Kenvue Inc. reported revenue, net income and margins by fiscal period, from SEC filings.
Period	Form	Revenue	Net income	Operating margin
FY 2025	10-K	$15.1B	$1.5B	16.0%
FY 2024	10-K	$15.5B	$1.0B	11.9%
FY 2023	10-K	$15.4B	$1.7B	16.3%
FY 2022	10-K	$14.9B	$2.1B	17.9%
FY 2021	10-K	$15.1B	$2.1B	19.4%

Institutions holding KVUE

Institutional investors reporting a position in Kenvue Inc. on SEC Form 13F.
Institution	Shares	Value	Reported
FMR	157,051,418	$3.0B	2026-06-30
BlackRock	150,825,694	$2.9B	2026-06-30
VANGUARD CAPITAL MANAGEMENT	125,314,564	$2.4B	2026-06-30
STATE STREET	121,619,054	$2.3B	2026-06-30
VANGUARD PORTFOLIO MANAGEMENT	93,303,762	$1.8B	2026-06-30
GEODE CAPITAL MANAGEMENT	52,021,320	$990.2M	2026-06-30
Pentwater Capital Management	51,130,000	$977.1M	2026-06-30
Independent Franchise Partners LLP	50,427,994	$963.7M	2026-06-30
NORGES BANK	46,156,826	$882.1M	2026-06-30
MASSACHUSETTS FINANCIAL SERVICES	44,715,586	$861.9M	2026-06-30

SEC EDGAR: CIK 1944048 →

Kenvue Inc.

KVUE

NYSELarge CapConsumer Staples

13F Pro Quality Score

60.3/100

Rank #865 of 2,961 stocksTOP 50%

View Consumer Staples peers →

Rankings refresh quarterly once 80% of peers have filed (~45 days after quarter-end). Next update: ~Nov 14, 2026.

Revenue Growth

23.8/100

Profitability

68.2/100

Balance Sheet

74.7/100

Earnings Quality

50.0/100

Free Cash Flow

60.5/100

Institutional Flow

69.6/100

Revenue Scale

90.4/100

Dilution Risk

60.1/100

Price Chart

Email me the moment this company reports earnings

AI Research Report

Two-page plain-English analysis: business, thesis, and three scenarios for the next two years. Refreshed every quarter.

Upgrade to Pro

Pro: 5 reports/month · Pro+: unlimitedOpinion, not investment advice. Do your own research.

What's Driving KVUE's Business? Latest 10-Q Breakdown

15/15 datapoints verified

AI-extracted from the 10-Q filed 2026-08-06 — Q2 FY2026 (quarter ended June 28, 2026). Every figure is machine-verified against the filing text on SEC EDGAR.

Net sales rose 3.0% YoY to $4.0B on broad-based segment growth, but gross margin contracted 70bps to 58.2% on input cost inflation and tariffs, while a pending $ Kimberly-Clark acquisition and reopened acetaminophen litigation loom over the quarter.

Biggest Revenue Drivers

Self Care$1,589M+2.2% YoY

Favorable value realization from EMEA/North America pricing offset by volume declines from lower illness incidence in Allergy, pediatric Pain Care, and Cough/Cold

Essential Health$1,253M+2.3% YoY

Volume gains from e-commerce, Wound Care innovation, and Baby Care promotions, partly offset by Oral Care declines from competitive pressure

Biggest Revenue Drivers

Total revenue: $4.0B+3.0% YoY

Self Care$1,589M+2.2% YoY

Favorable value realization from EMEA/North America pricing offset by volume declines from lower illness incidence in Allergy, pediatric Pain Care, and Cough/Cold

Essential Health$1,253M+2.3% YoY

Volume gains from e-commerce, Wound Care innovation, and Baby Care promotions, partly offset by Oral Care declines from competitive pressure

Skin Health and Beauty$1,113M+5.1% YoY

Favorable value realization plus volume gains from e-commerce, product innovation, and hair regrowth products

Largest Expense Items

Cost of sales$1,654M+4.8% YoY

Net input cost inflation, tariffs on U.S. imports, and unfavorable transactional FX, partly offset by supply chain optimization benefits

Selling, general, and administrative expenses$1,537M+2.2% YoY

Higher brand support and Pending Transaction costs, partly offset by restructuring savings and a $16M drop in Separation-related costs

Restructuring expenses$59M-1.7% YoY

Costs under the 2026 Restructuring Initiative to optimize the operating model and supply chain

Margins: Gross profit margin declined 70bps YoY to 58.2%, driven by net input cost inflation, U.S. tariffs, and unfavorable transactional FX, partially offset by supply chain optimization benefits and favorable pricing/mix.

Watch Items from the Filing

Pending acquisition by Kimberly-Clark: Kenvue shareholders to receive 0.14625 K-C shares plus $3.50 cash per share, expected to close Q4 2026 pending remaining foreign regulatory approvals.
In July 2026 the Second Circuit vacated the District Court's prior judgment favoring JJCI in the acetaminophen/autism multi-district litigation and remanded for further proceedings, reviving litigation exposure.
Company estimates gross tariff exposure of approximately $80 million annualized from U.S. import tariffs, with continued uncertainty following the Supreme Court's IEEPA ruling and new baseline tariffs.
Skin Health and Beauty reporting unit's estimated fair value exceeded carrying value by only ~10% in the September 2025 interim goodwill test; a 100bps increase in discount rate would trigger impairment.
Skin Health and Beauty segment adjusted operating income grew 24.8% YoY to $186M, driven by favorable pricing and lower brand support costs from media cost improvements.

AI-extracted and verified against SEC EDGAR filing text. Not investment advice.

Read the full 10-Q on SEC EDGAR →